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Glycosylation is one of the most prevalent post-translational modifications of a protein, with a defining
impact on its structure and function. Many of the proteins involved in the innate or adaptive immune
response, including cytokines, chemokines, and antimicrobial peptides (AMPs), are glycosylated,
contributing to their myriad activities. The current availability of synthetic coupling and
glycoengineering technology makes it possible to customise the most beneficial glycan modifications for
improved AMP stability, microbicidal potency, pathogen specificity, tissue or cell targeting, and
immunomodulation.
Introduction
AMPs are ubiquitous, ancient, and highly effective host defense
compounds that are a prominent aspect of the early innate im-
mune response to infection. They vary in sequence and length, but
are generally less than 30 amino acids, with a tendency to have a
cationic charge that attracts them to bacterial membranes. Their
mode of action is also diverse, ranging from direct integration and
permeabilisation of the cell wall, binding with nucleic and enzyme
targets, to indirect activity, such as immunomodulation of the
host. AMPs are often synthesised in an inactive form and then
post-translationally cleaved into an active state.
Glycosylation increases the protein and/or peptide diversity and
extends their range of functionality. Four distinct types of glyco-
sylation are currently known and being profoundly studied: N-, O-,
C-, and S-glycosylation. The type of the glycosylation depends on
the nature of the sugar–peptide bond and can be further diversified
on the base of glycosidic linkage, glycan composition, structure,
and length. N-type glycosylation, in which glycan is attached to
the amino group of asparagine, is well studied. Oligosaccharides
attach covalently upon recognition of the Asn-X-Ser/Thr (where X
is any amino acid) via a nitrogen atom. Many bacterial glycosyl-
transferases are already in use for in vitro controlled glycosylation,
resulting in the field of protein glycoengineering [1,2].
O-linked glycosylation is a dynamically explored field because
of its potent role in mammalian pathophysiological processes.
Defects in glycosylation in humans have broadly studied links
to different diseases and malfunctions [3]. O-linked glycosylation
is characterised by the covalent attachment of glycan through an
oxygen atom. However, the O-linked consensus, unlike the N-
linked one, is not as easily predictable [4]. It is initiated by the
attachment of GalNac to Ser/Thr, but can also comprise O-linked
b-N-acetylglucosamine; thus, classification of O-glycans is based
on their initiating monosaccharide [5]. The glycan polymer can
vary in heterogeneity, which makes the prediction of glycan
building blocks variable in vivo. Additionally, the further branch-
ing of the O-glycans involves multiple glycosyltransferases, and
our understanding of their function and structure is still in a
discovery stage.
Protein C-linked glycosylation differs fundamentally from N-
and O-glycosylation and defines a type of glycosylation in which a
carbohydrate is linked to a protein via a carbon atom. In eukar-
yotes, C-glycosylation has been detected in multiple cell lines (e.g.,
human RNase 2 and IL-12 and rat liver microsomes) [6]. The
biological role of C-glycosylation is still being elucidated, although
the interest of the pharmaceutical industry in the C-glycosylation
of proteins is related to its unique resistance to metabolic hydro-
lysis [7]. For C-mannosylation, the acceptor sequence comprises
W-x-x-W, where the first Trp becomes C-mannosylated [8].
S-linked glycosylation is the most recent discovery, described
for the first time as a post-translational modification of the
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sublancin glycopeptide [9], later also found in other bacteriocins
[10]. In S-linked glycosylation, the hexose residue is linked to the
thiol group of cysteine. An in vitro study of the glycotransferase
SunS showed that the enzyme can transfer glucose as well as any
hexose to multiple cysteine residues [9]. Therefore, the relaxed
substrate specificity of S-glycotransferase is similar to that of N-
glycosylation, and might have wide application in protein and/or
peptide engineering.
By 1998, glycosylation had been described in five naturally
occurring insect-derived AMPs, all O-linked, and proline rich:
diptericin, drosocin, formaecin, lebocin, and phyrrorricin [11].
Whereas O-linked glycosylation appears to favour proline-rich
regions, modifications are sometimes also observed in glycine-rich
regions [12]. A curated database of AMPs describes many hundreds
of different AMPs from humans, fishes, insects, reptiles, amphi-
bians, molluscs, and crustaceans (http://aps.unmc.edu/AP/main.
php). Although most are post-translationally modified in some
manner, such as C-terminal amidation, cyclisation, or the forma-
tion of disulfide bridge(s), only a small fraction, around a dozen or
so, are listed as carrying glycosylation motifs (most of these so-
called ‘gAMPs’ are insect derived). Therefore, gAMPs represent a
small subclass of AMPs, with broad-spectrum effects [11]. It is
becoming clear that the glycosylation of both natural and syn-
thetic AMPs can influence their antimicrobial activity, and their
ability to affect host immunity, target specificity, and biological
stability [13,14] (Fig. 1).
Glycosylation and antimicrobial activity
O-linked glycosylation of proline-rich AMPs has an important, and
often essential, role in their antimicrobial activity. By far the most
abundant type of O-glycosylation of prokaryotic and eukaryotic
peptides is the N-acetylgalactosamine (GalNAc) attachment to
serine (Ser) or threonine (Thr) by a glycosidic linkage, as occurs
in O-mannosylation, O-fucosylation, or O-glucosylation [15–17].
The importance of glycosylation has been well studied among
the insect AMPs, such as diptericin and formaecin and the
bacteriocin-family member, enterocin F4-9 [18,19]. In all the
above-mentioned peptides, the absence of glycosylation abolishes
their antimicrobial activity. Treatment of enterocin with the
deglycosylating enzyme, N-acetylglucosaminidase, cleaved the
O-linked GlcNac linkage from Ser and Thr residues and resulted
in a loss of activity [20]. In fish, the glycosylation and glycation of
skin gelatin peptides showed enhanced activity against multiple
species of bacteria, as well as antioxidant activity [21]. Finally,
plants also produce gAMPs to defend against fungal pathogens.
One recently identified gAMP, datucin, contains a terminal
GlcNac-asparagine, which shows activity against both planktonic
and biofilm Candida albicans, and even against multidrug-resistant
clinical strains [22].
Evidence of glycosylation affecting the function of human AMP
is scarcer, but has been documented [17]. Eosinophil cationic
protein (ECP) is exceptionally large compared with typical AMP,
but shares many of the same properties with the smaller peptides,
such as membrane-lysis activity and affinity towards lipopolysac-
charide (LPS) [15]. It is one of many proteins that are presynthe-
sised and stored in granules in readiness to be released upon
infection by parasitic invaders. Given that this is a relatively
nonspecific process, in the sense that it can be triggered by many
different species, diversity among the sequences and the post-
translational modifications of AMP is advantageous [16,17]. In-
deed, the level of glycosylation can account for as much as 3 kDa of
the total mass of the ECP. Concurrently, damage to the host is a
harmful consequence of such broad activity. The extent to which
the native form ECP is glycosylated with N-linked oligosaccharides
is influential. It is currently thought that heavily glycosylation of
ECP limits cytotoxicity, and only upon degranulation is the pro-
tein deglycosylated to its low-molecular-weight form, which
shows greatest cytotoxicity and enhanced lysis of model liposomes
[16]. Further evidence that glycosylation of this AMP protects the
host from harm comes from the identification of a single nucleo-
tide polymorphism that introduces an additional locus for glyco-
sylation, which reduces cytotoxicity without affecting catalytic
activity [17,23].
Glycosylation of AMP does not necessarily result in generation
of an efficacious peptide and can sometimes lead to a loss of
activity or functionality. As an example, the prokaryotic AMP
lysostaphin becomes glycosylated when expressed in mammalian
cells, and loses potency against its target, Staphylococcus aureus
[24]. Huang et al. identified the precise amino acid glycosylation
site on lysostaphin that resulted in the peptide being able to bind,
but no longer lyse, S. aureus. A single amino acid substitution
prevented glycosylation and restored lysostaphin lytic activity
[24]. Therefore, it is important to take into consideration the
differential expression of peptides among hosts to avoid undesired
types of glycosylation [25].
Finally, there are some remarkable examples of AMPs that are
not themselves glycosylated but whose function depends upon a
larger glycoprotein. Jellein is one such AMP, located within the
larger amino acid sequence of major royal jelly protein 1 (MRJP1).
Mannosylation of MRJP1-derived peptides facilitates the aggluti-
nation of bacteria through interaction with lectin receptors,
whereupon jelleins are able to lyse the bacteria in an example
of synergy between glycosylated proteins and nonglycosylated
peptides [26].
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FIGURE 1
The broad-spectrum effects of glycosylation and its possible utilisation for
antimicrobial peptide (AMP) optimisation. Abbreviation: BBB, blood–brain
barrier.
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Glycosylation and stability
The glycosylation profile of a peptide not only has a significant
role in its antimicrobial properties, but can also improve peptide
stability and biological properties both in vitro and in vivo. Table 1
summarises the examples of glycosylated AMPs and the specific
effect of their glycosylation, as described in this review.
Several studies have explored the effects of N-glycosylation on
peptide rigidity [27], solubility [28], propensity to aggregate [29],
conformational changes to the secondary structure of peptides
[30], and their ability to influence interactions with neighbouring
peptides [31]. This last trait effectively allows glycopeptides to
adopt chaperone-like qualities, and has been implicated as having
a protective role in preventing fibril formation that contributes to
amyloid diseases [29]. More than simply the presence or absence of
a glycan, variation in the conformation of the glycosylation affects
the stereoisometry of an AMP and can influence its stability. For
example, depending on the position of the amino acid that is
glycosylated, the linkage of a-D-GalNAc-Thr to the AMP, droso-
cin, alters its rigidity and antibacterial activity [18]. Different types
of glycosylation have the ability to influence the rate of fibril
formation in prion proteins, where N-glycans reduce the rate of
fibrilisation and O-glycans affect the rate of folding [28].
The energetics of N-glycan stabilisation is still being studied;
however, Levy et al. showed that peptide folding is accelerated
because of the intrinsic chemical properties of N-glycans that drive
the folding energy landscape by entropic restriction [20]. The
thermodynamic stabilisation induced by glycosylation is coupled
with kinetic stabilisation [32]. The N-glycan chaperone role is well
known to be the stabilising force for disulfide bond formation and
proline isomerisation during b-turns or b-sheet formation [33].
Peptide stability is an area that has particular prominence in the
pharmaceutical synthesis of therapeutic peptides, where it can be
affected by factors including pH and temperature, as well storage
and delivery conditions. Peptide glycosylation offers rich possibil-
ities in terms of the degree of glycosylation, and glycan type,
structural composition, and size. There are also various options
for the site of glycan attachment on the protein, which could bring
even greater heterogeneity.
The application of tailored glycosylation of AMP has the poten-
tial to modify many biological properties of the peptide in vivo,
where N-linked glycosylation has been shown to be effective in
modifying the serum half-life and bioavailability of peptides and
other compounds [34,35]. Enfuvirtide is a novel antiretroviral drug
in which glycosylation with sialic acid residues extends its half-life
more than tenfold, without affecting its sensitivity towards the
target [36]. The pharmacokinetics of glycosylation via the addition
of N- or O-glycans has been found to be similar to the addition of
polyethylene glycol moieties (PEGs), which increase the rigidity of
AMPs, protecting them from rapid renal clearance [37]. Such
modifications aim to increase the size of a given peptide, because
molecules with a molecular weight of <5 kDa that are not associ-
ated with plasma proteins tend to be excreted rapidly via the renal
system [34]. Glycomodification is preferable to PEG modification
because it does not pose the same safety concerns through intro-
duction of a synthetic polymer, and is technically less challenging
to achieve [14,38].
Almost all eukaryotic glycoproteins retain a conserved
sequence for glycosylation [39]. In vivo, many secreted proteins
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TABLE 1
Examples of glycosylated AMPs
AMP name Source Natural/synthetic
modification
Glycosylation type Role of glycan
Bactenecin Bovine neutrophils Natural, synthetic O-glycosylation Immunomodulation, regulation, activity
Chromacin G Bovine Natural O-linked (NeuAca2–3Galb1–3GalNAca1) Antibacterial activity, structural
advantages, proteases resistance
Datucin Plant Natural O-linked GlcNac Antifungal Activity
Diptericin Drosophila Natural O-linked Antibacterial activity
Drosocin Insect Natural, synthetic O-linked (a-D-GalNAc-Thr/
b-DGal(1/3)a-D-GalNAc-Thr)
Antibacterial activity
Enterocin F4-9 Bacteria Natural, synthetic O-linked Antibacterial activity
Eosinophil cationic
protein (ECP)
Human Natural N-linked Activity switch, stability
Formaecin Insect Natural O-linked Antibacterial activity
Glycocin F Bacteria Natural O-linked, S-linked (N-acetylglucosamine
b-O-linked to Ser18, and an
N-acetylhexosamine
S-linked to C-terminal Cys43)
Antibacterial activity, stability
Lactoferrin h-LF Human, mammalian Natural N-linked (highly branched N-glycans,
highly sialylated and fucosylated)
Stability, regulatory
Lebocin Tobacco hornworm Natural O-linked Antibacterial activity, resistance to proteases
Microcin E492 Bacteria Natural, synthetic C-glycosylated moiety Evasion of innate immune system,
attack of competing bacteria
Pyrrhocoricin Insect Natural O-linked Antibacterial activity
Sublancin Bacteria Natural S-linked Antibacterial activity
Tyrocidine A Bacteria Natural, synthetic N-linked Antibacterial activity
www.drugdiscoverytoday.com 3
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are co-translationally N-glycosylated with a preformed oligosac-
charide at specific amino acid motifs, namely Asn-X-Thr/Ser,
before translocation to the endoplasmic reticulum [40]. This nat-
ural process has been artificially replicated by the discovery of an
amino acid sequence, termed the Enhanced Aromatic Sequon
(EAS), which is even more efficiently glycosylated. The EAS can
be added to a variety of proteins, and often leads to more rapid
protein folding and enhanced stability through better hydropho-
bic interactions [41].
In bacteria, the N-glycosylation of Asn residues of the AMP,
tyrocidine A, produced by the soil bacterium Bacillus brevis,
promotes circularisation of this peptide. Studies of synthetic deri-
vatives of tyrocidine A demonstrated the importance of glycosyl-
ation, which allows the peptide to fold into its preferential
structure without affecting its antimicrobial properties [42]. AMPs,
such as bacteriocins, are also more stable in the face of acidic
conditions when they are in their circularised conformation,
making them attractive for oral administration.
An alternative strategy is to utilise S-linked glycosylation, which
has been shown to improve the peptide half-life in serum because
of its substantial resistance to proteolysis [10]. Therapeutic pep-
tides and proteins face stability issues in vivo partly because of the
action of proteolytic enzymes. Glycosylation can help either by
masking the peptide from proteinases or by changing the confor-
mation of the peptide to make it more compact or sheltered [43].
In natural systems, S-linked glycosylation occurs post-translation-
ally at the cysteine residue, allowing sulfur-a-carbon bridges to
form, giving conformational strength similar to disulfide bonds.
An example is glycocin F, which is an S-linked glycopeptide from
the bacteriocin family with a remarkable stability across a wide pH
range (2–10) and resistance to boiling for up to 2 h [10]. Promis-
ingly, the activity of S-glycosyl transferase has been shown to have
relaxed substrate specificity, making it an attractive tool for syn-
thetic gAMP design [9]. The considerable advantages offered by the
glycosylation of therapeutic peptides highlights the need to de-
velop general approaches to predict the structural consequences of
site-specific ‘designer’ glycosylation. This is rather limited to the
trial and error method of testing synthesised glycoproteins. There
is a growing market for glycopeptide synthesis, which not only
offers help in the design of glycopeptides, but also provides
screening and large-scale services (e.g., Bachem and Gly Tech
partnership merger).
Glycosylation and target specificity
Besides their inherent microbicidal properties, the potency of a
given AMP is defined by its target specificity. As components of
innate immunity, AMPs are a diverse family with a broad-spectrum
effect, ranging from different species of bacteria, viruses, and fungi
to some cancer cells. Although some AMPs are broad acting,
glycosylation offers a means to tailor an AMP to a precise molecu-
lar target. Most of the microorganisms rely on glycan-recognition
receptors to invade the host cells [44]. Microbes display pathogen-
associated molecular patterns (PAMPs) on their surfaces, which are
recognised by lectin receptors on the host cells. An understanding
of host–pathogen interactions would enable the design of a spe-
cific glycosylated AMP that recognises a certain PAMP, specific to a
certain microbe, resulting in the highest interspecies selectivity
[26].
The ability to modify AMPs to distinguish so carefully between
different bacteria has obvious benefits when multiple species are
competing for limited resources, and indeed, examples of gAMPs
influencing bacterial competition have been observed. For in-
stance, glycocin F is secreted by Lactobacillus plantarum in the
presence of competing bacteria. This peptide has an O-linked N-
acteylglucosamine that is essential for its activity with additional
S-linked N-acetylhexosamine, which increases its bacteriostatic
potency [10]. The precise mechanism of action of glycocin F is
unknown, but is thought to be result from glycosylation motifs
that selectively target lectins displayed by susceptible cells [45].
Plantaricin is another antimicrobial peptide of the bacteriocin
family, active against competing lactobacilli and secreted by
L. plantarum. The lethal mode of action of this peptide results
from a selective membrane interaction that causes rapid cell lysis
[46]. The exact mechanism of selectivity lies in the preferential
affinity of the peptide towards the glycosylated surface proteins of
competitors. The removal of the negative charge of the surface
glycoprotein reduced the activity of plantaricin, which was de-
pendent on glycosylation patterns displayed on the surface [47].
Other bacteriocins have been shown to interact directly with
mannose phosphotransferase system (PTS) transporters found
in some bacterial membranes. For example, microcin MccE492
interacts with a surface-expressed mannose transporter on Gram-
negative bacteria [48]. Microcin MccE492 is a small (<10 kDa)
ribosomal peptide toxin secreted by enterobacteria to enhance
host colonisation by preventing the growth of competitive species
[49]. Interestingly, the gene cluster encoding microcin MccE492
also enables an unusual post-translational modification, namely
an attachment of a monoglycosylated derivative of enterobactin
to the MccE492m C-terminus [50]. The result is a C-glycosidic
bond that bridges the ribosomal and nonribosomal peptide frag-
ments of Mcc492, shaping the toxin into its active structure. This
natural modification is also feasible for a synthetic approach to
design new antibiotics specific against Gram-negative species.
Among mammalian AMPs, the bovine peptide, chromacin, is
unusual because it carries a net negative, rather than a positive,
charge and is hydrophilic, suggesting that it should have poor
affinity towards bacterial membranes. However, it is still able to
inhibit Gram-positive bacteria [51]. Strub and colleagues revealed
that O-glycosylation at Ser186 is required for its activity [51]. The
glycosylation directs the peptide towards a specific cell surface
receptor, overcoming the natural limitations in affinity to bacteria
caused by its inherent chemical properties.
Conversely, glycosylation of target sites rather than of the AMPs
themselves can represent an important aspect of AMP specificity.
In the case of a synthetic AMP, PAF26, glycosylation is a liability
for the fungal pathogen, and removal of the fungal glycosylation
system enhanced its resistance to PAF26 [52]. Such examples have
also been found among non-infectious diseases. The affinity of
AMP towards glycoproteins expressed at the host cell surface has
been described as a mechanism of selectivity towards cancerous
cells, leaving healthy cells unaffected [47,53]. Likewise, the cat-
ionic AMP, sapecin, containing Lys-Leu-Lys motifs, interacts with
negatively charged sialic acid moieties on host eukaryotic mem-
branes [54].
Not all AMPs function by disrupting lipid membranes and
causing cell lysis. Proline-rich peptides, such as apidaecin or
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bactenecin, act against intracellular targets. The ability of some
AMPs to modify host immunology is at least as valuable as their
direct antimicrobial activity. A classic example is the neutrophil
AMP, proline-arginine rich peptide (PR-39), which was among the
first mammalian nonpore-forming AMPs to be described. It was
shown to regulate NADPH oxidase activity, limit excessive tissue
damage during inflammation, promote angiogenesis, and aid
wound repair [55,56]. PR-39 was also implicated in protecting
against the metastasis of certain types of cancer by inducing
syndecan-1, which is a heparin sulfate proteoglycan involved in
the differentiation and prognosis of many types of cancer [57].
Other AMPs have been shown to have diverse systemic effects
on the immune system, including cytokine production, and the
ability to act as chemokines, to interact with major histocompati-
bility complexes (MHCs), to stimulate dendritic cells, B cells and T
cells [58], and to differentiate macrophages (reviewed in [59]). The
specific contribution of glycosylation to these activities is yet to be
elucidated, but the propensity for these immune-modifying pep-
tides to be proline rich and commonly associated with glycosyla-
tion, suggests an underinvestigated area of research.
Immunomodulation by gAMP
Different glycosylation patterns are linked with different immune
responses, and the T cell repertoire includes receptors, named
Tcarb, that specifically recognise glycopeptides complexed with
MHC-I and MHC-II [60]. Their specificity towards glycans was
shown to be dependent upon the amino acid composition of
the T cell receptor at a specific glycan-recognising region within
the abTCR CDR3 region [61].
Interestingly, abTcarb cells are poor at recognising large, com-
plex glycan structures; therefore, any large branched sugars at-
tached to an antigen would be hidden from recognition by abTcarb
cells [58]. However, larger glycans that are poorly recognised by
abTcarb and MHC-II might be able to directly engage with recep-
tors on B cells and stimulate gdT cells, which have roles from
wound healing to combating tumours and parasitic infections
[62]. The direct activation of the B cell receptor by an antigen is
most efficient through cross-linking mechanisms that result from
recognition of repetitive and ordered structures that are typical of
protein aggregates or capsular saccharides [63]. In vaccinology,
this effect can be mimicked via the glycosylation of proteins to
form a protein–glycan conjugate that promotes B cell receptor
clustering, inducing the humoral and memory immunity against
the associated pathogen. Early studies using this methodology
revealed that the size of the glycan was a crucial aspect in
eliciting an effective response, as measured by serum immuno-
globulin levels [35]. These myriad properties of glycosylated
peptides raise not only concerns, but also opportunities for
the rational modification of AMP. Their immunogenicity is an
important consideration in the clinical development of new
peptides, because immune cells readily generate antibodies
against foreign peptide epitopes. This is a problem particularly
in repeated dosing, when neutralising antibodies would promote
clearance of the peptide or worse, cause adverse inflammatory
responses. Indeed, glycosylation of ‘self’ epitopes to make them
appear ‘nonself’ has been described to contribute to chronic
autoimmune diseases, such as type 1 diabetes mellitus and
rheumatoid arthritis [64,65].
Peptide immunogenicity can be tailored depending upon the
desire to increase or reduce its immunogenicity. For example, O-
linked or N-linked sialic acid residues can have a masking effect
against T cell and B cell receptors [66]. Otherwise, glycosylation
can be used to enhance immunogenicity, either in the form of an
adjuvant, or as a direct therapy [67]. An excellent example is the
design of a glycopeptide that displays high affinity for MHCs and T
cell receptors, and is decorated with the same carbohydrate anti-
gen as expressed by tumour cells, the Thomsen-Freidenreich (TF)
antigen (beta-Gal-[1!3]-alpha-GalNAc-O-serine) [68] to train im-
munity against a range of cancers; this could represent a future
gAMP vaccine.
Rational design of antimicrobial peptides
In recent years, AMPs have been viewed with both hope and
consternation. On the one hand, they offer new tools to combat
rising antimicrobial resistance to traditional medication and they
are broadly effective against many species at low concentrations.
On the other hand, they are limited in terms of their bioavailabili-
ty and stability in vivo. Glycosylated AMPs could offer the means to
finally overcome many of these limitations.
One such a drawback, as well as an advantage, of AMPs is their
broad-spectrum activity, which can raise concerns of selectivity
between mammalian and bacterial membranes that is largely
distinguished because of the ionic differences between these
two. Furthermore, AMPs can themselves be immunogenic, or be
neutralised by host immune factors. To decrease the reactivity
of AMPs within the host, they can be decorated with glycans
derived from bacteria, via either chemical conjugation, synthetic
approaches, or recombination expression systems. An example of
such glycan is polysialic acid, derived from Neisseria meningitidis or
Escherichia coli, which renders the peptide less immunogenic. This
is because of a structural mimicry with host cell lectins or analo-
gues of sialic acid, which allow the glycosylated peptide to be
immune quiescent. The structural mimicry of the N. meningitidis
glycan to polysialic acid (PSA) suppresses complement deposition
and phagocytosis [69]. Overall, because of their enormous diversi-
ty and applicability in biopharmaceutical proteins modifications,
sialic acids and their analogues represent a separate field of exten-
sive research. Desialylated proteins are rapidly removed from the
blood circulation; therefore, conjugating AMP with sialic acid
could improve its circulatory half-life. Moreover, sialic acids show
potential in the design of blood–brain barrier (BBB)-penetrating
peptides, helping to deliver the treatment to the central nervous
system. O-linked glycosylation was shown to improve the BBB
penetration of an opioid peptide as well as markedly increasing the
serum and brain stability of that peptide [70,71]. In the future,
BBB-penetrating glycans could be used to help target infections
of the nervous system, facilitating elimination of persistent
infections and improving therapeutic bioavailability [72].
Moreover, because most AMPs interact with human cell mem-
branes, they could be used as delivery vehicles for bioactive
compounds [73]. For example, to deliver an AMP to hepatocytes,
one could tag it with a glycan that interacts with the asialoglyco-
protein receptor (ASGPR), also known as the hepatic galactose/N-
acetyl-glucosamine receptor [74]. Another example of the useful
modification of AMP would be collectin targeting. Collectins
contribute to innate immunity by stimulating rapid phagocytosis,
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chemotaxis, and the production of cytokines [75]. There are many
different types of organ-specific collectin, such as SP-A and SP-D,
which are found in lung and intestine, respectively [76] and which
could be excellent targets for the aerosol delivery of AMP in the
treatment of lung infections. Peptides with targeted antimicrobial
properties are ultimately the main goal to progress most of the
currently known AMPs into clinical trials [77].
The utility of using bacterial mimicry of eukaryotic carbohy-
drates to decorate AMP can also be seen with the O-antigen of
Helicobacter pylori, which shows targeted interaction with Galectin-
3 on gastric epithelial cells. The O-antigen of H. pylori mimics in
structure human Lewis blood group antigens, leading to immune
avoidance by bacteria so that the host recognises the bacterial
antigens as ‘self’. H. pylori O-antigen is decorated with fucose
residues and N-acetylneuraminic acid, similar to human sialic
acids. Therefore, the rational design of gAMP inspired by this
system could aid in both tissue-specific targeting and immune
avoidance.
Indeed, knowledge of ligand–receptor interactions can be ap-
plied to target gAMP to individual cell types; for example, the
interaction between N-acetylgalactosamine with asialoglycopro-
tein on the surface of hepatocytes [78] or targeting C-type lectin
receptors to stimulate phagocytosis to target intracellular infec-
tion. Delivering gAMP to intracellular targets could also be en-
hanced by the research undertaken on cell-penetrating peptides
(CPPs). This showed that glycans improve the hydrophilic pro-
pensities of cationic peptides, without the cost of increased cell
cytotoxicity, as sometimes occurs when hydrophobic, balancing
amino-acids are introduced [79].
Concluding remarks and future perspectives
There has been much progress in our understanding of glycobiol-
ogy in recent years, with applications in vaccinology, cancer
biology, and immunology, and potentially revolutionising the
field of gAMP design and synthesis. Some antimicrobial peptides
are already in clinical use, including ambicin (nisin), polymyxin B,
and gramicidin S, with several more in development (reviewed in
[80]). The immunomodulatory properties of AMPs have already
been applied in what is a conceptually fascinating new tool in the
fight against drug-resistant bacteria. Derivatives of the proline-rich
bovine AMP, bactenecin, were shown to induce recruitment of
immune cells efficient in fighting infection,as demonstrated
in vitro [81] and in vivo [82]. Antimicrobial drug development
no longer aims to only fight infections, but also to improve
systemic health and reduce the general drug toxicity/adverse
effects of some antibiotics currently available.
We have emphasised here that glycosylation offers a new aspect
to the well-known activity of standard AMPs. Current computer
databases containing novel, well-characterised saccharides make it
easier to determine which glycan type could be utilised to benefit
the overall properties of a therapeutic peptide [83]. Glycan libraries
for combinatorial design contain all kinds of glycan, from N/-O-
glycans, oligosaccharides, glycosaminoglycans, and mammalian
glycans to microbial oligosaccharides [84].
It is also possible to search for glycans with specified backbone
types (https://glycosciences.med.ic.ac.uk/glycanLibraryIndex.
html). A tailored peptide can be visualised in silico in a 3D form
allowing selection of the most beneficial exposure and/or mask-
ing of immunogenic epitopes (PDB2multiGif). Moreover, the
structure and conformational information can be modelled
using the GlycoMaps software, providing additional informa-
tion before empirical testing [85]. To assess the stability of the
peptide and predict its activity, it might be beneficial to deter-
mine the influence of glycosylation on hydrophobicity [86] and
additional van der Waals interactions [84] (e.g., using Sweet-II
[87]). These glycotools can be combined with well-developed
tools for the computer-aided design of AMPs and structure–
activity modelling software to estimate antimicrobial activity
versus quantitative structure–activity relationships (QSAR)
[88,89,90].
Such databases facilitate the design of novel gAMPs, from
which point there are several synthesis options readily available.
The traditional solid-phase synthesis of AMP can produce
a peptide that can be chemically conjugated with a glycan
[90,91].
Alternatively, the peptides can be expressed by recombinant
bacteria, and subsequently glycosylated by plasmid-encoded
enzymes. Such glycoengineering offers great potential for the
custom glycosylation of target peptides [1]. Mammalian cell line
expression systems have also been successfully used, particularly
for O-glycosylated peptides [92]. These platforms will inevitably
speed up the process of developing new peptide therapeutics, and
allow the precise improvement of existing ones. Coupled with
high-throughput screening assays of libraries of gAMPs, glycoen-
gineering now offers a relatively fast, cheap, and efficient way to
optimise the properties of lead compounds.
The combination of our expanding understanding of the role of
natural glycosylation of AMPs in living organisms, the accessibility
of large protein and saccharide databases, advanced modelling
software, and the huge strides that have been made in glycoengi-
neering, together create the perfect foundation for the design of a
new class of therapeutics that hold great potential: glycosylated
AMPs.
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